In vivo evaluation of aggregated tau or associated pathophysiology in AD was first performed using immunoassays for cerebrospinal fluid (CSF) tau phosphorylated at position 181 (p-tau) [3]. This evidence concerns the gene MAPT and Alzheimer disease.